Archives of Disease in Childhood 2009;94:224-226
SHORT REPORTS
Henoch-Schönlein purpura and meningococcal B vaccination
1 Meningococcal Vaccine Strategy, Ministry of Health, Wellington, New Zealand
2 Middlemore Hospital, Manukau, New Zealand
3 Auckland City Hospital, Auckland, New Zealand
Anne McNicholas, Meningococcal Vaccine Strategy, Ministry of Health, PO Box 5013, Wellington, New Zealand; anne_mcnicholas{at}moh.govt.nz
The risk of Henoch-Schönlein purpura (HSP) following vaccination with a group B meningococcal vaccine was assessed through active hospital safety monitoring. There was no increase in the relative incidence of HSP within 30 days after vaccination nor recurrence in HSP cases who received one or more further vaccine doses (re-challenge).
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
- Full Text
- Full Text (PDF)
-
All Versions of this Article:
adc.2007.125195v1
94/3/224 most recent - Submit a response
- Alert me when this article is cited
- Alert me when eLetters are posted
- Alert me if a correction is posted
Services
- Email this link to a friend
- Similar articles in ADC Online
- Similar articles in PubMed
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
